Table 1.

Currently available agents against the IGF pathway evaluated in clinical trials for the treatment of HCC

Compound	Company	Mechanism of action	Phase of clinical development	Trial Status	Intervention	Type of Cancer
MEDI-573	MedImmune LLC	Fully Human mAb anti- IGF1 and –IGF2	1b/2	Completed	In combination with sorafenib	Unresectable or metastatic HCC
IMC-A12	National Cancer Institute	Fully Recombinant Human mAb anti- IGF1R	2	Completed	Alone	Adult Primary, advanced, localized unresectable, recurrent HCC
	National Cancer Institute		1	Active, not recruiting	In combination with sorafenib tosylate	Advanced HCC
	Eli Lilly and Company		2	Active, not recruiting	In combination with sorafenib	Advanced HCC
BIIB-022	BiogenIdec	Human IgG4P nonglycosylated antibody anti-IGF1R	1b	Completed	In combination with sorafenib	Advanced HCC
AVE-1640	Sanofi-Aventis	Humanized mAb anti- IGF1R	1/2	Completed	Alone and in combination with sorafenib and erlotinib	HCC not eligible for local treatment
OSI-906	AstellasPharmaInc	Small molecule inhibitor of IGF1R	2	Completed	Alone	With advanced HCC after failure of first-line treatment with sorafenib

Data from clinicaltrials.gov.